FAQ

Any PI employed with a Partner University may apply to beLAB1407. Any post-doc who is contracted to be employed by the University for at least the expected duration of a funded project may also apply with a letter of support from a PI. All applicants should contact their local TTO prior to official application.

The EIR along with the local beLAB1407 representative is intended to be a valuable resource for academics wishing to consult a drug discovery expert on how to best shape and plan projects as well as provide initial feedback as to the suitability of the project idea for beLAB1407. The remit of the EIR is to add value across the Universities drug discovery activities, to help identify and position new applications and to work in a highly integrated fashion with the university organisation as well as other beLab1407 stakeholders to ensure the smooth conduct of the partnership.

Applicants benefit from financial support for funded projects and from the combined technical expertise and physical resources of the beLab1407 partners in building and implementing early stage drug discovery and development programmes. The early involvement of the TTO aims to provide support in the identification of any third party rights to the proposed project proposal and provide an initial understanding of the competitive landscape. Should successful programmes be selected for further development and inclusion in a future spinout, then the beLab1407 management team, along with the respective TTO, aim to provide strategic guidance and governance in preparation of the commercial and scientific plan.

It is expected that the majority of funded projects will be undertaken at Evotec’s facilities, but project funding ultimately aims to recognize the expertise and unique capabilities of the applicant in order to build on synergies while avoiding redundancies and thus applications will be funded under which some or all of the work could be undertaken in the University. Please note that University work will be costed by your department at industrial FEC rates.

Prior receipt of proof of concept funding from external sources does not preclude an application, but such funding should be disclosed in an application and discussed with the local TTO to ensure eligibility.

All beLAB1407partners, including the Expert in Residence, are under a duty of confidentiality regarding information disclosed to them in the course of the partnership. However, information should not be disclosed to beLAB1407, which is subject to a duty of confidentiality to a 3rd party; for example, where research results have been generated from a project with a commercial sponsor. If in doubt, researchers should first check with their local TTO.

It is expected that the projects will be undertaken in line with the project proposal at Evotec and/or in the labs of the academic, wherever most appropriate.

For each awarded project, a dedicated project manager at Evotec will be appointed to work closely with the PI during the lifetime of the project. In addition, the PI will be responsible for providing updates on the project to the JSC upon request as well as raising any potential issues to the EIR, the local beLAB1407 representative or the JSC. At the completion of each project a full report, using a standard beLAB1407 template, is to be provided by the PI. Ultimately, any transitions to a next phase dependent upon reaching predefined milestones will be made and communicated by the JSC.

The beLAB1407 JSC and EIR will monitor progress and make go/no-go decisions should awards be tranched.

The applicant is expected to champion the project and will play an active role in guiding and managing the project.

Yes, provided that platform technologies have the primary purpose of generating new therapies.

beLAB1407 will not support clinical projects. It is not intended to provide funding for academics’ salaries over an extended period of time. beLAB1407 will not support basic research.